Sartorius, a German pharmaceutical and laboratory equipment supplier, on Tuesday said it would invest in a new production line for pallet tanks used in single-use bioreactors (vessels that support biological processes, such as chemical reactions, cell growth, or tissue development) at its R&D facility in Bengaluru until 2027 to meet local and global demands.
The company also said it has plans to nearly double its annual capacity for manufacturing and testing chromatography (a process for separating components of a mixture) systems in 2025.
The company has invested $202 million in R&D in 2024 and India, being the largest R&D site globally, has received a significant chunk of it, said the company.
According to Dr. Joachim Kreuzburg, Chairman- Executive Board of Sartorius AG,Chairman- Board of Directors of Sartorius Stedim Biotech S.A, India has been playing a vital role in the group’s global network, serving both local and international markets.
These investments would further enhance Sartorius’s ability to provide cutting edge solutions for biopharmaceutical manufacturing, the company said.
Sartorius’ India plant manufactures stainless steel components and bioreactor systems in the range of 5 litres to 6,500 litres, fermentation systems and high precision components for the biopharma industry. India is also a global hub for IT and digital solutions focusing on software lifecycle management and development, for Sartorius globally.
The company employs 700 people in India of which 45% are engineers.
Published – March 11, 2025 10:43 pm IST
